

Pascaline Boudou-rouquette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722472/publications.pdf>

Version: 2024-02-01

119
papers

3,125
citations

218677

26
h-index

168389

53
g-index

127
all docs

127
docs citations

127
times ranked

4685
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	7.0	257
2	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e37563.	2.5	252
3	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	10.7	222
4	Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 1034-1041.	6.4	204
5	Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i> -positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	1.8	140
6	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017, 83, 125-131.	2.8	134
7	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011, 6, 253-258.	3.6	117
8	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 2046-2049.	2.6	95
9	Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis. <i>Oncologist</i> , 2012, 17, 1204-1212.	3.7	91
10	Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGT1A9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study. <i>PLoS ONE</i> , 2012, 7, e42875.	2.5	88
11	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	4.4	88
12	Drug interactions with solid tumour-targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 179-196.	4.4	85
13	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1139-1147.	4.7	74
14	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	2.6	73
15	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
16	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 928-940.	5.6	62
17	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 174-183.	2.8	50
18	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 257-268.	2.6	47

#	ARTICLE	IF	CITATIONS
19	Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1477-1488.	7.3	43
20	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. <i>Medical Oncology</i> , 2012, 29, 2793-2799.	2.5	40
21	Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. <i>Annals of Oncology</i> , 2012, 23, 280-281.	1.2	38
22	Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients. <i>Pharmaceutical Research</i> , 2011, 28, 3199-3207.	3.5	36
23	An HPLC-LIV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 928, 93-97.	2.3	35
24	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 30-36.	2.8	35
25	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	2.8	32
26	Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 785-794.	3.3	31
27	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	3.7	28
28	Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. <i>Annals of Oncology</i> , 2008, 19, 1975.	1.2	26
29	Resting energy expenditure in the risk assessment of anticancer treatments. <i>Clinical Nutrition</i> , 2018, 37, 558-565.	5.0	25
30	Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis. <i>Oncology</i> , 2013, 84, 32-38.	1.9	22
31	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 98-107.	1.9	22
32	Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PATients) cohort. <i>Journal of Geriatric Oncology</i> , 2020, 11, 586-592.	1.0	22
33	Cost Effectiveness of Integrated Medicine in Patients With Cancer Receiving Anticancer Chemotherapy. <i>Journal of Oncology Practice</i> , 2012, 8, 205-210.	2.5	20
34	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	2.6	20
35	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	3.3	19
36	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSÀ© pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11520-11520.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. <i>Anti-Cancer Drugs</i> , 2012, 23, 739-744.	1.4	18
38	Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 745-748.	1.4	16
39	Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 104-109.	2.0	16
40	How to Optimize Cancer Treatment in Older Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 109-116.	1.3	16
41	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. <i>Journal of Medical Genetics</i> , 2020, 57, 104-108.	3.2	16
42	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	5.0	16
43	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021, 150, 108-118.	2.8	16
44	Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 663-673.	2.4	15
45	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. <i>Oral Oncology</i> , 2019, 95, 79-86.	1.5	15
46	Depressive Symptom Profiles and Survival in Older Patients with Cancer: Latent Class Analysis of the ELCAPA Cohort Study. <i>Oncologist</i> , 2019, 24, e458-e466.	3.7	15
47	Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1051-1055.	2.3	14
48	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	2.5	13
49	Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. <i>Oncotarget</i> , 2017, 8, 34245-34257.	1.8	13
50	Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 287-297.	2.3	12
51	Imprint cytology in tumor tissue bank quality control: an efficient method to evaluate tumor necrosis and to detect samples without tumor cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 443-447.	2.8	11
52	First referral to an integrated onco-palliative care program: a retrospective analysis of its timing. <i>BMC Palliative Care</i> , 2020, 19, 31.	1.8	11
53	Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4105-4111.	7.0	11
54	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	7.0	10

#	ARTICLE	IF	CITATIONS
55	Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. <i>Investigational New Drugs</i> , 2012, 30, 1756-1760.	2.6	9
56	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. <i>Oncologist</i> , 2015, 20, e26.	3.7	9
57	Postoperative Outcome of Surgery with Pancreatic Resection for Retroperitoneal Soft Tissue Sarcoma: Results of a Retrospective Bicentric Analysis on 50 Consecutive Patients. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2299-2306.	1.7	9
58	Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. <i>International Journal of Cancer</i> , 2022, 150, 645-653.	5.1	9
59	Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. <i>Supportive Care in Cancer</i> , 2012, 20, 2235-2239.	2.2	8
60	Sorafenib for patients with differentiated thyroid cancer. <i>Lancet</i> , The, 2015, 385, 227-228.	13.7	8
61	Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort. <i>Cancers</i> , 2022, 14, 244.	3.7	8
62	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 673-687.	4.1	7
63	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1033-1039.	2.3	7
64	A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1196-1200.	2.5	7
65	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	2.3	7
66	Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3055-3055.	1.6	7
67	Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11504-11504.	1.6	6
68	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	6.1	6
69	Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. <i>Clinical Nutrition</i> , 2022, 41, 1073-1082.	5.0	6
70	Nutritional Status Is Superior to the ECOG Performance Status in Predicting the Dose-Intensity of the GEMOX Chemotherapy Regimen in Patients with Advanced Cancer. <i>Nutrition and Cancer</i> , 2013, 65, 1254-1257.	2.0	5
71	Cervical extravasation of bevacizumab. <i>Anti-Cancer Drugs</i> , 2013, 24, 426-428.	1.4	5
72	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. <i>Oncologist</i> , 2014, 19, e3.	3.7	5

#	ARTICLE	IF	CITATIONS
73	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. <i>American Journal of the Medical Sciences</i> , 2018, 356, 404-407.	1.1	5
74	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	3.7	5
75	Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	2.3	4
76	Soluble VEGFR-1: A new biomarker of sorafenib-related hypertension. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 478-479.	2.0	3
77	Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results. <i>Annals of Oncology</i> , 2016, 27, vi530.	1.2	3
78	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6377-6377.	7.0	3
79	Higher complications after previous external beam radiation for extremity soft-tissue sarcoma in the surgical treatment of a local recurrence: a comparative retrospective study of one hundred and three patients. <i>International Orthopaedics</i> , 2019, 43, 727-733.	1.9	3
80	Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. <i>Pharmaceutics</i> , 2022, 14, 1224.	4.5	3
81	Abstract 4546: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort. <i>Cancer Research</i> , 2018, 78, 4546-4546.	0.9	2
82	Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11552-11552.	1.6	2
83	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 3214.	3.7	2
84	Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 257-283.	0.5	1
85	Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review. <i>European Journal of Cancer</i> , 2020, 130, 20-22.	2.8	1
86	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	1.9	1
87	How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15592-e15592.	1.6	1
88	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 170-170.	1.6	1
89	Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9620-9620.	1.6	1
90	Evaluation of baseline asymptomatic dysimmunity prevalence in cancer patients receiving monoclonal anti-PD1 antibodies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14551-e14551.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Effect of nivolumab therapy on pulmonary artery.. Journal of Clinical Oncology, 2017, 35, e18266-e18266.	1.6	1
92	Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 11544-11544.	1.6	1
93	A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer.. Journal of Clinical Oncology, 2022, 40, 12011-12011.	1.6	1
94	Reply to Bone morphogenetic proteins and zoledronic acid. Annals of Oncology, 2009, 20, 2019.	1.2	0
95	How should we manage bevacizumab toxicity in lung cancer patients?. Lung Cancer Management, 2014, 3, 355-363.	1.5	0
96	L'information sur le pronostic: quel sens pour les patients?. Medecine Palliative, 2015, 14, 98-110.	0.0	0
97	Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma. Journal of the Endocrine Society, 2017, 1, 72-74.	0.2	0
98	Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group. International Journal of Cancer, 2021, , .	5.1	0
99	Sarcoligo: Impact of local ablative treatment of oligometastatic sarcomas on overall survival.. Journal of Clinical Oncology, 2012, 30, 10042-10042.	1.6	0
100	Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis. Blood, 2012, 120, 4786-4786.	1.4	0
101	Arterial stiffness to predict hypertensive response to antiangiogenic drugs.. Journal of Clinical Oncology, 2013, 31, e13589-e13589.	1.6	0
102	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients.. Journal of Clinical Oncology, 2014, 32, 9551-9551.	1.6	0
103	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20523-e20523.	1.6	0
104	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors.. Journal of Clinical Oncology, 2015, 33, e13569-e13569.	1.6	0
105	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
106	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0
107	A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochin hospital experience.. Journal of Clinical Oncology, 2016, 34, e18208-e18208.	1.6	0
108	Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).. Journal of Clinical Oncology, 2017, 35, 11047-11047.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0
110	Clinical and pharmacological parameters associated with nivolumab toxicity.. Journal of Clinical Oncology, 2018, 36, 3066-3066.	1.6	0
111	Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. Journal of Clinical Oncology, 2018, 36, 11523-11523.	1.6	0
112	Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.. Journal of Clinical Oncology, 2018, 36, e22133-e22133.	1.6	0
113	Abstract 1693: Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients. , 2018, , .		0
114	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. Journal of Clinical Oncology, 2019, 37, e22506-e22506.	1.6	0
115	A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.. Journal of Clinical Oncology, 2020, 38, 11506-11506.	1.6	0
116	Abstract 4107: Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab efficacy in advanced non-small cell lung cancer. , 2019, , .		0
117	Abstract 4955: Impact of PD-1, PD-L1 and EB13 on prognosis in a cohort of localized high grade undifferentiated pleomorphic sarcoma patients. , 2019, , .		0
118	Health literacy in patients with cancer: A multicenter national study.. Journal of Clinical Oncology, 2022, 40, 6541-6541.	1.6	0
119	REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. Journal of Clinical Oncology, 2022, 40, TPS11585-TPS11585.	1.6	0